Document is current
Any future updates will be listed below
-
Authors
Rydén, Mikael
-
Funding
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (Clinical Scholar)
ERC (Synergy)
Vetenskapsrådet
Karolinska Institute
- License Information
-
More Information
Article History
Received: 5 February 2026
Accepted: 6 March 2026
First Online: 24 April 2026
Funding
: Open access funding provided by Karolinska Institute. MR’s work is supported by grants from the Swedish Research Council, the Novo Nordisk Foundation, Knut and Alice Wallenberg Foundation (Clinical Scholar), CIMED, the Strategic Research Program in Diabetes at Karolinska Institutet, ERC-SyG SPHERES, the Swedish Diabetes Foundation, the Stockholm County Council, and Konung Gustaf V:s och Drottning Victorias Stiftelse.
: MR has received speaker honoraria from Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi. MR has also participated in international and national advisory boards for Boehringer Ingelheim, Novo Nordisk, Sanofi and Sigrid Therapeutics. In addition, MR has participated, together with AstraZeneca, in the organising committee for a meeting on cardiorenal–metabolic disease in Mölndal, Sweden. Finally, MR has received funding for a postdoctoral fellow through a joint project with Novo Nordisk, exploring novel targets in human adipocytes. None of these engagements are related to the present review.
: MR was the sole contributor to this paper.
